BELOGAL Trademark

Trademark Overview


On Wednesday, March 2, 2016, a trademark application was filed for BELOGAL with the United States Patent and Trademark Office. The USPTO has given the BELOGAL trademark a serial number of 79192560. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, September 29, 2023. This trademark is owned by Double Bond Pharmaceuticals AB. The BELOGAL trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, anti-cancer preparations and preparations for treatment of central nervous system diseases, immune system disorders, metabolic diseases, lung diseases, and bacterial and fungal infections; pharmaceutical preparations for tissue targeting for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections; pharmaceutical preparations for controlled release of anti-cancer drugs and drugs for the treatment of immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections; chemical preparations for pharmaceutical purposes, namely, for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections; chemical preparations for medical purposes, namely, for the treatment of cancer, immune system disorders, central n...
belogal

General Information


Serial Number79192560
Word MarkBELOGAL
Filing DateWednesday, March 2, 2016
Status709 - CANCELLED - SECTION 71
Status DateFriday, September 29, 2023
Registration Number5158538
Registration DateTuesday, March 14, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 27, 2016

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, anti-cancer preparations and preparations for treatment of central nervous system diseases, immune system disorders, metabolic diseases, lung diseases, and bacterial and fungal infections; pharmaceutical preparations for tissue targeting for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections; pharmaceutical preparations for controlled release of anti-cancer drugs and drugs for the treatment of immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections; chemical preparations for pharmaceutical purposes, namely, for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections; chemical preparations for medical purposes, namely, for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections; chemical preparations for veterinary purposes, namely, for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections in mammals; veterinary preparations for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections in mammals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, September 29, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameDouble Bond Pharmaceuticals AB
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressSE

Party NameDouble Bond Pharmaceuticals AB
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressSE

Party NameDouble Bond Pharmaceuticals AB
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressSE

Trademark Events


Event DateEvent Description
Tuesday, October 4, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 4, 2016ASSIGNED TO EXAMINER
Saturday, October 8, 2016APPLICATION FILING RECEIPT MAILED
Saturday, October 1, 2016SN ASSIGNED FOR SECT 66A APPL FROM IB
Thursday, October 6, 2016NON-FINAL ACTION WRITTEN
Friday, October 7, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, December 7, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 27, 2016PUBLISHED FOR OPPOSITION
Tuesday, December 27, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 14, 2017REGISTERED-PRINCIPAL REGISTER
Wednesday, June 14, 2017FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, June 21, 2017FINAL DISPOSITION PROCESSED
Saturday, October 15, 2016TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 27, 2016REFUSAL PROCESSED BY MPU
Thursday, October 27, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, November 1, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, November 1, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 1, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 10, 2016NEW REPRESENTATIVE AT IB RECEIVED
Friday, November 18, 2016REFUSAL PROCESSED BY IB
Monday, November 21, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 21, 2017FINAL DISPOSITION NOTICE SENT TO IB
Saturday, July 8, 2017FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, September 29, 2023CANCELLED SECTION 71
Friday, June 14, 2024TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Thursday, June 27, 2024INVALIDATION PROCESSED
Friday, November 23, 2018NEW REPRESENTATIVE AT IB RECEIVED
Monday, March 14, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Thursday, June 27, 2024TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Saturday, July 20, 2024TOTAL INVALIDATION PROCESSED BY THE IB